Wednesday, 25th of May 2011 |
Best viewed at http://www.nature.com/news/2011/110525/full/473434a.html
Published online 25 May 2011 | Nature 473, 434-435 (2011) | doi:10.1038/473434a
News Feature
Vaccination campaigns against measles have had dramatic results — but eradicating the disease is still a distant prospect.
This article is best viewed as a PDF
Great advances in the development and distribution of vaccines mean that some diseases can be eradicated. Measles is an important case study: efforts to stem the disease have been successful, but uneven political commitment, lack of funds and public fear threaten to undermine the progress.
PAST: A KILLER CRUSHED
In 1980, before vaccination was widespread, there were around 4 million cases of measles and an estimated 2.6 million deaths from the disease worldwide1. Childhood mortality targets set by the United Nations, along with accelerated control programmes, have cut the proportion of childhood deaths caused by measles from 7% in 1990 to 1% in 20082.
PRESENT: TROUBLE SPOTS
Ideally, 95% of children need to receive two doses of a measles-containing vaccine to interrupt disease transmission. By 2009, almost 60% of countries had achieved 90% coverage with at least one dose — but some are still far below this, and some are slipping backwards.
United States Measles was officially eliminated in 2000, but cases imported from elsewhere threaten to reestablish the virus. More cases have been registered in 2011 than in any year since 1996, leading to fears of outbreaks among unvaccinated children.
India India is struggling to reduce deaths from measles3, mainly because of a lack of money and political will to provide two doses of vaccine to all children. There are some indications that this is changing.
Europe More than 30,000 measles cases were reported in 2010, five times more than the annual average for the past five years4. Many have been traced back to a major Bulgarian outbreak in 2009–10. Unfounded fears over the measles, mumps and rubella (MMR) vaccine have contributed to the resurgence.
Africa Outbreaks have been seen in 28 countries in the past two years5, mainly because of a lack of funding and political commitment to follow-up vaccination campaigns, and problems with vaccine delivery. There has also been resistance among some religious groups in Zimbabwe, Botswana, Malawi and South Africa.
FUTURE: FUNDING FEARS AND UNCERTAINTY
Because measles deaths have fallen, vaccination efforts now compete for funding with other diseases, so investment has dropped. Some countries are struggling to introduce the recommended second dose of measles-containing vaccine, let alone new vaccines — for invasive pneumococcal disease and rotavirus, for example — that could save many more lives.
Assuming no catch-up immunizations in troubled countries, public-health officials predict a worst-case scenario in which the death toll could exceed 500,000 by 20131.
In a 'status-quo' scenario, modest increases in first-dose vaccine coverage are complemented by catch-up immunizations at about 2008 levels — but this still falls short of global eradication.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41264469 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |